Background Non-high-density lipoprotein cholesterol （non-HDL-C） and Apolipoprotein B （apoB） increase car- diovascular disease （CVD） risk, but few studies have explored the correlations of non-HDL-C and apoB with cor- onary atherosclerosis in non-diabetes acute coronary syndrome （ACS）. Methods The study enrolled 443 sub- jects with non-diabetic ACS, and all subject check coronary angiography, and coronary atherosclerosis were eval- uated using Gensini Score （GS） scale including small （GS 1-15）, middle （GS16-43）, and severe （GS≥44）. All sub- jects were classified into 4 groups： High apoB （≥90 mg/dL） and High non-HDL-C （≥130 mg/dL）, High non-HDL -C alone, High apoB alone, and normal apoB and non-HDL-C. Results After adjusted for risk factors, non-HDL -C and apoB were positively correlated with GS （ r = 0.075, P = 0.002 and r = 0.092, P 〈 0.001）. In the GS 0-15, high non-HDL-C ＋ high apoB group 29.3% and high apoB alone group 28.2% were significantly lower than nor- mal non-HDL-C＋ normal apoB group 48% （p = 0.010）. In the GS 16-43, high non-HDL-C alone group 50.4% and high apoB alone group 47.6% were significantly more than high non-HDL-C＋ high apoB group 34.1% （P = 0.036）. In the GS ≥44, high non-HDL-C＋ high apoB group 36.6% was significantly higher than high non-HDL- C alone group 16% and normal non-HDL-C＋ normal apoB 14.2%（P 〈 0.001）. Conclusions The high non-HDL- C and apoB are the risk factors for coronary artery atherosclerosis in non-diabetic ACS.
Clinical application of implantable cardioverter defibrillator （ICD） can significantly reduce the incidence of sudden cardiac death （SCD）. However, ICD cannot prevent ventricular tachycardia （VT） or ventricu- lar fibrillation （VF）. Previous studies indicated that ICD combined with reasonable anti-arrhytbmic drug therapy can improve anti-arrhythmic effect. EMIAT, CAMIA and OPTIC trials reported that combined treatment of Ami- odarone and β receptor blockers was superior to their treatment alone. Therefore, it is necessary to give anti-at- rhythmic treatment alter 1CD implantation. Methods Totally 180 ICD implantation recipients enrolled in our hospital from Jan 2011 to March 2014. Among them, 39 recipients were treated with Amiodarone （Group A）, 89 recipients were treated with β blocker （Group B）, and 52 recipients were treated with Amiodarone combined with β blocker （Group C） after ICD implantation. Patients were followed up for 3 to 40 months by monitoring the heart rate, LVEF Value and rapid ventricular arrhythmias events. Results There were no significant differences on heart rate before and after ICD implantation among the three groups （P = 1.28, P = 0.85）, but the change of heart rate was statistically higher （P = 0.04） in Group B compared with Group A and Group C. There were no sta- tistical significance in LVEF value before ICD implantation and after ICD implantation and the change of LVEF value （P = 0.56, P = 0.50, P = 0,99）. The occurrence rate of rapid ventricular arrhythmias in Group A （10.26%） and Group B （10.11%） was significantly higher （P = 0.04） than in Group C （1.92%）. which wae slight- ly increased by Amiodarone in Group A and Group C. There were 2 cases of thyroid dysfunction in Group A, 1 case in Group C and no case in Group B. No pulmonary interstitial fibrosis cases were found in this study. Conclusions Combined treatment with Amiodarone and β receptor blockers could significantly reduce rapid ven- tricular arrhythmias when compared
